PharmAust Limited
ASX:PAA.AX
0.23 (AUD) • At close October 14, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | PharmAust Limited |
Symbool | PAA.AX |
Munteenheid | AUD |
Prijs | 0.23 |
Beurswaarde | 111,926,052 |
Dividendpercentage | 0% |
52-weken bereik | 0.068 - 0.535 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Michael Thurn Ph.D. |
Website | https://www.pharmaust.com |
An error occurred while fetching data.
Over PharmAust Limited
PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (AUD)
Cijfers zijn in miljoenen (AUD)